Inhaled corticosteroids. Beclojet as a drug with a new delivery system
Abstract
Beclojet is a dosed freon-free aerosol inhaler containing beclomethazone dipropionate and a jet delivery system. The aim of this study was to investigate clinical efficacy and safety of Beclojet in moderate to severe bronchial asthma patients who had been treated before with inhaled and/or systemic glucocorticodteroids (GCS).
Forty patients aged 18 to 65 years have received Beclojet for 2 months in doses equal to those of previously given inhaled GCS or in combination with previously given systemic GCS without growing of their doses. The efficacy was evaluated before and after the therapy with Beclojet on the background of BA drug stability according to the need of β-agonists, daytime and nighttime BA symptoms, lung function parameters. The effectiveness of Beclojet was compared with the previous therapy with inhaled GCS.
The Beclojet application in moderate to severe BA patients was quite effective at various clinical situations. There was not adverse events for the 2-month follow-up period. The drug was easy to use, economically reasonable (it was cheaper than other inhaled GCS). The results allow to recommend Beclojet for widespread application as the basic BA therapy.
About the Authors
T. V. Latysheva
ГНЦ Институт иммунологии Минздрава РФ
Russian Federation
Russian Federation
O. V. Romanova
ГНЦ Институт иммунологии Минздрава РФ
Russian Federation
Russian Federation
References
1. Ведущие направления в диагностике и лечении бронхиальной астмы. Основные положения отчета группы экспертов EPR2: Пер. с англ. под ред. А.Н.Цой, М.: Грантъ; 1998.
2. Глобальная стратегия лечения и профилактики бронхиальной астмы. М.: Атмосфера; 2002. 89-99.
3. Емельянов A.B., Тренделева Т.E., Краснощекова О.И. и др. Терапевтические возможности применения высоких доз беклометазона дипропионата у больных бронхиальной астмы. Аллергология 2002; 1: 41-43.
4. Ильина Н.И. Ингаляционные глюкокортикоиды. Астма.ги. Аллерг. респиратор, забол. 0*2001; пилот, вып.
5. Ильина Н.И., Червинская Т.А., Латышева Т.В. и др. Клиническая и фармакоэкономическая эффективность Беклоджета у больных бронхиальной астмой. В кн.: IX Российский нац. конгресс "Человек и лекарство". Тезисы докладов. М.; 2002. 180.
6. Синопальников А.И., Клячкина И.Л. Средства для доставки лекарств в дыхательные пути при бронхиальной астме. Рус. мед. вести 2003; 1: 15-21.
7. Суточникова O.A. Ингаляционные ГКС — наиболее эффективные и безопасные противовоспалительные препараты для лечения астмы. Рус. мед. журн. 1997; 5 (17): 1115-1120.
8. Цой А.Н. Параметры фармакокинетики современных ингаляционных глюкокортикостероидов. Пульмонология 1999; 2: 73.
9. Barnes P.J., Pedersen 'S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Care Med. 1998; 157 (3, pt 2, suppl.): 1-53.
Review
For citations:
Latysheva T.V., Romanova O.V. Inhaled corticosteroids. Beclojet as a drug with a new delivery system. PULMONOLOGIYA. 2003;(5):100-104. (In Russ.)
Views:
332
Email this article 